-+ 0.00%
-+ 0.00%
-+ 0.00%

Sumitomo Heavy starts Fujita Health [18F]FBPA PET trial for deep-seated cancer diagnosis

PUBT·09/01/2026 05:41:24
Listen to the news
Sumitomo Heavy starts Fujita Health [18F]FBPA PET trial for deep-seated cancer diagnosis
  • Sumitomo Heavy Industries launched a specified clinical trial at Fujita Health University using its MPS200FBPA-made PET agent [18F]FBPA.
  • Study targets hard-to-classify deep-seated abdominal lesions, aiming to support tumor diagnosis and inform future BNCT use in deep-seated cancers.
  • No results have been presented; data are expected in the future during the Aug. 6, 2026 to March 31, 2028 study period.
  • Outcome focus is whether [18F]FBPA PET/CT can improve differentiation of malignant tumors from non-neoplastic lesions using pathology as reference.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Heavy Industries Ltd. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.